Corinne Jenkins
Stock Analyst at Goldman Sachs
(1.76)
# 2,943
Out of 4,831 analysts
62
Total ratings
42.86%
Success rate
-2.85%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Corinne Jenkins
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| RYTM Rhythm Pharmaceuticals | Maintains: Buy | $59 → $66 | $56.79 | +16.22% | 8 | Dec 5, 2024 | |
| TGTX TG Therapeutics | Maintains: Neutral | $20 → $22 | $33.37 | -34.07% | 8 | Nov 5, 2024 | |
| FULC Fulcrum Therapeutics | Upgrades: Buy | $6 → $15 | $5.79 | +159.07% | 2 | May 14, 2024 | |
| IDYA IDEAYA Biosciences | Maintains: Buy | $53 → $46 | $17.45 | +163.61% | 5 | May 13, 2024 | |
| ROIV Roivant Sciences | Maintains: Buy | $16 → $18 | $10.76 | +67.29% | 5 | Apr 3, 2024 | |
| GERN Geron | Maintains: Buy | $4 → $5 | $1.20 | +316.67% | 3 | Mar 15, 2024 | |
| ALT Altimmune | Reinstates: Neutral | $13 | $5.76 | +125.69% | 3 | Jan 24, 2024 | |
| HRMY Harmony Biosciences Holdings | Maintains: Sell | $25 → $28 | $34.37 | -18.53% | 7 | Jan 9, 2024 | |
| SWTX SpringWorks Therapeutics | Maintains: Buy | $47 → $52 | $46.22 | +12.51% | 5 | Nov 29, 2023 | |
| BTAI BioXcel Therapeutics | Maintains: Neutral | $192 → $64 | $1.43 | +4,375.52% | 6 | Aug 15, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $27 → $23 | $0.75 | +2,975.28% | 2 | Mar 15, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $25 → $21 | $1.22 | +1,621.31% | 2 | Mar 7, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $9 → $14 | $2.90 | +382.76% | 2 | Dec 20, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $9 → $8 | $29.51 | -72.89% | 2 | May 24, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | $16 | $0.28 | +5,614.29% | 2 | Dec 15, 2021 |
Rhythm Pharmaceuticals
Dec 5, 2024
Maintains: Buy
Price Target: $59 → $66
Current: $56.79
Upside: +16.22%
TG Therapeutics
Nov 5, 2024
Maintains: Neutral
Price Target: $20 → $22
Current: $33.37
Upside: -34.07%
Fulcrum Therapeutics
May 14, 2024
Upgrades: Buy
Price Target: $6 → $15
Current: $5.79
Upside: +159.07%
IDEAYA Biosciences
May 13, 2024
Maintains: Buy
Price Target: $53 → $46
Current: $17.45
Upside: +163.61%
Roivant Sciences
Apr 3, 2024
Maintains: Buy
Price Target: $16 → $18
Current: $10.76
Upside: +67.29%
Geron
Mar 15, 2024
Maintains: Buy
Price Target: $4 → $5
Current: $1.20
Upside: +316.67%
Altimmune
Jan 24, 2024
Reinstates: Neutral
Price Target: $13
Current: $5.76
Upside: +125.69%
Harmony Biosciences Holdings
Jan 9, 2024
Maintains: Sell
Price Target: $25 → $28
Current: $34.37
Upside: -18.53%
SpringWorks Therapeutics
Nov 29, 2023
Maintains: Buy
Price Target: $47 → $52
Current: $46.22
Upside: +12.51%
BioXcel Therapeutics
Aug 15, 2023
Maintains: Neutral
Price Target: $192 → $64
Current: $1.43
Upside: +4,375.52%
Mar 15, 2023
Maintains: Buy
Price Target: $27 → $23
Current: $0.75
Upside: +2,975.28%
Mar 7, 2023
Maintains: Buy
Price Target: $25 → $21
Current: $1.22
Upside: +1,621.31%
Dec 20, 2022
Maintains: Buy
Price Target: $9 → $14
Current: $2.90
Upside: +382.76%
May 24, 2022
Maintains: Neutral
Price Target: $9 → $8
Current: $29.51
Upside: -72.89%
Dec 15, 2021
Initiates: Neutral
Price Target: $16
Current: $0.28
Upside: +5,614.29%